OncoMatch/Clinical Trials/NCT05764954

A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma

Is NCT05764954 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NovoTTF-200T System for adenocarcinoma of lung.

Phase 1RecruitingMemorial Sloan Kettering Cancer CenterNCT05764954Data as of May 2026

Treatment: NovoTTF-200T System — The researchers are doing this study to find out if treatment with TTFields using the NovoTTF-200T System is safe and practical (feasible) before surgical removal (resection) of lung adenocarcinoma (ADC). The researchers will also look at how the treatment may help the body's immune system to fight cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Required: Stage 1A2, 1A3, IB

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

Memorial Sloan Kettering Basking Ridge (Consent Only) · Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Consent Only) · Middletown, New Jersey
Memorial Sloan Kettering Bergen (Consent Only) · Montvale, New Jersey
Memorial Sloan Kettering Suffolk - Commack (Consent Only) · Commack, New York
Memorial Sloan Kettering Westchester (Consent Only) · Harrison, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify